

Global Tardive Dyskinesia Therapeutics Market Size Study & Forecast, by Drug (Deutetrabenazine, Valbenazine, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies), and Regional Analysis, 2023-2030

<https://marketpublishers.com/r/G26881F0F200EN.html>

Date: March 2024

Pages: 200

Price: US\$ 4,950.00 (Single User License)

ID: G26881F0F200EN

Abstracts

Global Tardive Dyskinesia Therapeutics Market is valued at approximately USD 2.33 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 9.1% over the forecast period 2023-2030. Tardive Dyskinesia (TD) therapeutics refer to treatments aimed at managing the symptoms of TD, a drug-induced movement disorder characterized by involuntary movements of the tongue, face, trunk, and extremities. These therapies primarily focus on improving the motor symptoms associated with TD, which can significantly impact patients' quality of life. The support of TD treatment involves the use of medications such as valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO), both of which are VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors). These drugs help regulate dopamine levels in the brain, thereby reducing abnormal movements caused by TD. Additionally, patients benefit from other supportive therapies, including physical therapy, occupational therapy, and speech therapy, aimed at improving motor control and functional abilities. Treatment plans for TD are often tailored to individual patient needs and may involve a combination of pharmacological and non-pharmacological interventions. The Tardive Dyskinesia Therapeutics Market is expanding because of factors such as the increasing prevalence of tardive dyskinesia, growing antipsychotic prescriptions, advancements in drug development, and increasing recognition and acceptance of mental health issues worldwide.

In addition, the rising government initiatives aimed at raising awareness about this disorder is poised to act as a catalyzing factor for market growth across the globe. Numerous countries have initiated government-sponsored programs designed to educate both the public and healthcare professionals about the causes, symptoms, and available treatment options for this condition. For instance, in May 2022, the U.S. government spearheaded Tardive Dyskinesia Awareness Week during the first full week of May. This nationwide awareness campaign engaged all 50 states and the District of Columbia, fostering a deeper understanding of this often-misunderstood orphan disease. Through collaborative efforts, the U.S. government sought to advocate for approximately 600,000 individuals in the U.S. affected by this condition. The upsurge in government initiatives is anticipated to propel market growth during the estimated period. Moreover, the increase in initiatives to boost patient engagement by innovative campaigns, as well as the growing emphasis on investing in research and development present various lucrative opportunities over the forecast years. However, the introduction of alternative options to these medications and the side effects associated with tardive dyskinesia therapeutics are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Tardive Dyskinesia Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing aging population, high prevalence of schizophrenia, increasing awareness, increasing healthcare expenditure, and the presence of well-established healthcare infrastructure. Whereas, Europe is expected to grow at the highest CAGR over the forecast years. The increasing research and development activities, supportive regulatory frameworks and expedited approvals for new therapies, and rising prevalence of this condition across the region, which will lead to the increase in demand for its treatment. According to a research paper published by the journal Psychiatry and Clinical Neurosciences in August 2022, the prevalence of TD was estimated at 23.3% in Europe. This offers a lucrative opportunity for the market players to launch novel products during the forecast period.

Major market players included in this report are:

Teva Pharmaceutical Industries Ltd

Neurocrine Biosciences, Inc

Sun Pharmaceutical Industries Ltd

SteriMax Inc.

Adamas Pharmaceuticals, Inc

Sanis

AbbVie Inc.

Mylan N.V,

Reddy's Laboratories Ltd,

Sun Pharmaceutical Industries Ltd

Recent Developments in the Market:

In May 2022, Neurocrine Biosciences unveiled groundbreaking findings on the effectiveness of INGREZZA (valbenazine) in enhancing tardive dyskinesia management and maintaining psychiatric symptom stability during the American Psychiatric Association Annual Meeting 2022.

In March 2022, Mitsubishi Tanabe Pharma Corporation received regulatory approval from the Ministry of Health, Labor, and Welfare for the use of DYSVAL capsules 40mg as a treatment for tardive dyskinesia. DYSVAL is a vesicular monoamine transporter type 2 (VMAT2) inhibitor.

In December 2021, Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. forged a co-promotion agreement for MT-5199, a vesicular monoamine transporter type 2 (VMAT2) inhibitor designated for treating tardive dyskinesia in Japan.

Global Tardive Dyskinesia Therapeutics Market Report Scope:

Historical Data – 2020 - 2021

Base Year for Estimation – 2022

Forecast period - 2023-2030

Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered - Drug, Distribution Channel, Region

Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug:

Deutetrabenazine

Valbenazine

Others

By Distribution Channel:

Hospital Pharmacies

Drug Stores & Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Contents

CHAPTER 1. EXECUTIVE SUMMARY

- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
 - 1.2.1. Tardive Dyskinesia Therapeutics Market, by Region, 2020-2030 (USD Billion)
 - 1.2.2. Tardive Dyskinesia Therapeutics Market, by Drug, 2020-2030 (USD Billion)
 - 1.2.3. Tardive Dyskinesia Therapeutics Market, by Distribution Channel, 2020-2030 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption

CHAPTER 2. GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET DEFINITION AND SCOPE

- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
 - 2.2.1. Industry Evolution
 - 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates

CHAPTER 3. GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET DYNAMICS

- 3.1. Tardive Dyskinesia Therapeutics Market Impact Analysis (2020-2030)
 - 3.1.1. Market Drivers
 - 3.1.1.1. Increasing prevalence of tardive dyskinesia
 - 3.1.1.2. Rising government initiatives
 - 3.1.2. Market Challenges
 - 3.1.2.1. Introduction of alternative options to these medications
 - 3.1.2.2. Side effects associated with tardive dyskinesia therapeutics
 - 3.1.3. Market Opportunities
 - 3.1.3.1. Surge increase in initiatives to boost patient engagement by innovative campaigns
 - 3.1.3.2. Growing emphasis on investing in research and development

CHAPTER 4. GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET INDUSTRY ANALYSIS

- 4.1. Porter's 5 Force Model
 - 4.1.1. Bargaining Power of Suppliers
 - 4.1.2. Bargaining Power of Buyers
 - 4.1.3. Threat of New Entrants
 - 4.1.4. Threat of Substitutes
 - 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Impact Analysis
- 4.3. PEST Analysis
 - 4.3.1. Political
 - 4.3.2. Economical
 - 4.3.3. Social
 - 4.3.4. Technological
 - 4.3.5. Environmental
 - 4.3.6. Legal
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. COVID-19 Impact Analysis
- 4.7. Disruptive Trends
- 4.8. Industry Expert Perspective
- 4.9. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DRUG

- 5.1. Market Snapshot
- 5.2. Global Tardive Dyskinesia Therapeutics Market by Drug, Performance - Potential Analysis
- 5.3. Global Tardive Dyskinesia Therapeutics Market Estimates & Forecasts by Drug 2020-2030 (USD Billion)
- 5.4. Tardive Dyskinesia Therapeutics Market, Sub Segment Analysis
 - 5.4.1. Deutetrabenazine
 - 5.4.2. Valbenazine
 - 5.4.3. Others

CHAPTER 6. GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

- 6.1. Market Snapshot
- 6.2. Global Tardive Dyskinesia Therapeutics Market by Distribution Channel, Performance - Potential Analysis
- 6.3. Global Tardive Dyskinesia Therapeutics Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
- 6.4. Tardive Dyskinesia Therapeutics Market, Sub Segment Analysis
 - 6.4.1. Hospital Pharmacies
 - 6.4.2. Drug Stores & Retail Pharmacies
 - 6.4.3. Online Pharmacies

CHAPTER 7. GLOBAL TARDIVE DYSKINESIA THERAPEUTICS MARKET, REGIONAL ANALYSIS

- 7.1. Top Leading Countries
- 7.2. Top Emerging Countries
- 7.3. Tardive Dyskinesia Therapeutics Market, Regional Market Snapshot
- 7.4. North America Tardive Dyskinesia Therapeutics Market
 - 7.4.1. U.S. Tardive Dyskinesia Therapeutics Market
 - 7.4.1.1. Drug breakdown estimates & forecasts, 2020-2030
 - 7.4.1.2. Distribution Channel breakdown estimates & forecasts, 2020-2030
 - 7.4.2. Canada Tardive Dyskinesia Therapeutics Market
- 7.5. Europe Tardive Dyskinesia Therapeutics Market Snapshot
 - 7.5.1. U.K. Tardive Dyskinesia Therapeutics Market
 - 7.5.2. Germany Tardive Dyskinesia Therapeutics Market
 - 7.5.3. France Tardive Dyskinesia Therapeutics Market
 - 7.5.4. Spain Tardive Dyskinesia Therapeutics Market
 - 7.5.5. Italy Tardive Dyskinesia Therapeutics Market
 - 7.5.6. Rest of Europe Tardive Dyskinesia Therapeutics Market
- 7.6. Asia-Pacific Tardive Dyskinesia Therapeutics Market Snapshot
 - 7.6.1. China Tardive Dyskinesia Therapeutics Market
 - 7.6.2. India Tardive Dyskinesia Therapeutics Market
 - 7.6.3. Japan Tardive Dyskinesia Therapeutics Market
 - 7.6.4. Australia Tardive Dyskinesia Therapeutics Market
 - 7.6.5. South Korea Tardive Dyskinesia Therapeutics Market
 - 7.6.6. Rest of Asia Pacific Tardive Dyskinesia Therapeutics Market
- 7.7. Latin America Tardive Dyskinesia Therapeutics Market Snapshot
 - 7.7.1. Brazil Tardive Dyskinesia Therapeutics Market
 - 7.7.2. Mexico Tardive Dyskinesia Therapeutics Market

7.8. Middle East & Africa Tardive Dyskinesia Therapeutics Market

7.8.1. Saudi Arabia Tardive Dyskinesia Therapeutics Market

7.8.2. South Africa Tardive Dyskinesia Therapeutics Market

7.8.3. Rest of Middle East & Africa Tardive Dyskinesia Therapeutics Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

8.1. Key Company SWOT Analysis

8.1.1. Company

8.1.2. Company

8.1.3. Company

8.2. Top Market Strategies

8.3. Company Profiles

8.3.1. Teva Pharmaceutical Industries Ltd

8.3.1.1. Key Information

8.3.1.2. Overview

8.3.1.3. Financial (Subject to Data Availability)

8.3.1.4. Product Summary

8.3.1.5. Recent Developments

8.3.2. Neurocrine Biosciences, Inc

8.3.3. Sun Pharmaceutical Industries Ltd

8.3.4. SteriMax Inc.

8.3.5. Adamas Pharmaceuticals, Inc

8.3.6. Sanis

8.3.7. AbbVie Inc.

8.3.8. Mylan N.V,

8.3.9. Reddy's Laboratories Ltd,

8.3.10. Sun Pharmaceutical Industries Ltd

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

9.3. Research Assumption

List Of Tables

LIST OF TABLES

TABLE 1. Global Tardive Dyskinesia Therapeutics Market, report scope
TABLE 2. Global Tardive Dyskinesia Therapeutics Market estimates & forecasts by Region 2020-2030 (USD Billion)
TABLE 3. Global Tardive Dyskinesia Therapeutics Market estimates & forecasts by Drug 2020-2030 (USD Billion)
TABLE 4. Global Tardive Dyskinesia Therapeutics Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
TABLE 5. Global Tardive Dyskinesia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 6. Global Tardive Dyskinesia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 7. Global Tardive Dyskinesia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 8. Global Tardive Dyskinesia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 9. Global Tardive Dyskinesia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 10. Global Tardive Dyskinesia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 11. Global Tardive Dyskinesia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 12. Global Tardive Dyskinesia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 13. Global Tardive Dyskinesia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 14. Global Tardive Dyskinesia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
TABLE 15. U.S. Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
TABLE 16. U.S. Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 17. U.S. Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
TABLE 18. Canada Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 19. Canada Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 20. Canada Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 21. UK Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 22. UK Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 23. UK Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 24. Germany Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 25. Germany Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 26. Germany Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 27. France Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 28. France Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 29. France Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 30. Italy Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 31. Italy Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 32. Italy Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 33. Spain Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 34. Spain Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 35. Spain Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 36. RoE Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 37. RoE Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 38. RoE Tardive Dyskinesia Therapeutics Market estimates & forecasts by

segment 2020-2030 (USD Billion)

TABLE 39. China Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 40. China Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 41. China Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 42. India Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 43. India Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 44. India Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 45. Japan Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 46. Japan Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 47. Japan Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 48. South Korea Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 49. South Korea Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 50. South Korea Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 51. Australia Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 52. Australia Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 53. Australia Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 54. RoAPAC Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 55. RoAPAC Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 56. RoAPAC Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 57. Brazil Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 58. Brazil Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 59. Brazil Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 60. Mexico Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 61. Mexico Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 62. Mexico Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 63. RoLA Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 64. RoLA Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 65. RoLA Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 66. Saudi Arabia Tardive Dyskinesia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)

TABLE 67. South Africa Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 68. RoMEA Tardive Dyskinesia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)

TABLE 69. List of secondary sources, used in the study of global Tardive Dyskinesia Therapeutics Market

TABLE 70. List of primary sources, used in the study of global Tardive Dyskinesia Therapeutics Market

TABLE 71. Years considered for the study

TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

List Of Figures

LIST OF FIGURES

- FIG 1. Global Tardive Dyskinesia Therapeutics Market, research methodology
 - FIG 2. Global Tardive Dyskinesia Therapeutics Market, Market estimation techniques
 - FIG 3. Global Market size estimates & forecast methods
 - FIG 4. Global Tardive Dyskinesia Therapeutics Market, key trends 2022
 - FIG 5. Global Tardive Dyskinesia Therapeutics Market, growth prospects 2023-2030
 - FIG 6. Global Tardive Dyskinesia Therapeutics Market, porters 5 force model
 - FIG 7. Global Tardive Dyskinesia Therapeutics Market, pest analysis
 - FIG 8. Global Tardive Dyskinesia Therapeutics Market, value chain analysis
 - FIG 9. Global Tardive Dyskinesia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
 - FIG 10. Global Tardive Dyskinesia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
 - FIG 11. Global Tardive Dyskinesia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
 - FIG 12. Global Tardive Dyskinesia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
 - FIG 13. Global Tardive Dyskinesia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
 - FIG 14. Global Tardive Dyskinesia Therapeutics Market, regional snapshot 2020 & 2030
 - FIG 15. North America Tardive Dyskinesia Therapeutics Market 2020 & 2030 (USD Billion)
 - FIG 16. Europe Tardive Dyskinesia Therapeutics Market 2020 & 2030 (USD Billion)
 - FIG 17. Asia pacific Tardive Dyskinesia Therapeutics Market 2020 & 2030 (USD Billion)
 - FIG 18. Latin America Tardive Dyskinesia Therapeutics Market 2020 & 2030 (USD Billion)
 - FIG 19. Middle East & Africa Tardive Dyskinesia Therapeutics Market 2020 & 2030 (USD Billion)
- List of tables and figures and dummy in nature, final lists may vary in the final deliverable

I would like to order

Product name: Global Tardive Dyskinesia Therapeutics Market Size Study & Forecast, by Drug (Deutetrabenazine, Valbenazine, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies), and Regional Analysis, 2023-2030

Product link: <https://marketpublishers.com/r/G26881F0F200EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G26881F0F200EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970